DOCSLIB.ORG

Pain Management

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Pain management Preeyaphan Arunakul MD FRCAT Department of Anesthesia Faculty of Medicine, Thammasat University Definition “An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage.” Classification of pain by time • Acute pain - Pain less than 12 weeks • Chronic pain - Pain longer than 12 weeks Nociceptive Nonnociceptive Somatic Visceral Neuropathic Psychogenic sharp, dull Poorly localized, Burning, electrical -Rarely pure aching deep squeezing, (lancinating), -No nociceptive or crampy numbing, neuropathic mechanism allodynia, can be identified -Myofascial hyperalgesia -With sufficient -Metastatic -Small bowel psychogenic symptoms bone pain obstruction -Postsurgical -Carcinomatosis -Trigeminal neuralgia -Arthritis peritonii -Postherpetic neuralgia -Painful peripheral neuropathy NSAIDs -CRPS I,II Opioids TCA/SSRI -Phantom limb pain Muscle relaxants Gabapentin Aniline deriv. Opioids Anticonvulsants Antidepressants Multimodalities Interventions Antidepressants Psychological therapy Psychotherapy Interventions Multimodalities Acute Postoperative Pain ผู้ป่วยมีอาการปวดเฉียบพลัน “5th Vital sign” มีสาเหตุที่ท าให้เกิดอาการปวด รักษาสาเหตุ ประเมินระดับความปวด ไม่ต้องการ อาการปวดต้องการการรักษาหรือไม่ ประเมินซ ้าและบันทึก ต้องการ (PS ≥ 4 หรือปวดปานกลางขึ้นไป) เครื่องมือที่ใช้ประเมินความปวด รักษาโดยใช้ยา - VAS/VRS/NRS รักษาโดยไม่ใช้ยา - FACE/FLACCs รักษาแบบผสมผสาน - CHEOPS ไม่ได้ผล การรักษาได้ผลดีหรือไม่ ปรึกษาผู้เชี่ยวชาญ ได้ผลดี เกิด เกิดภาวะแทรกซ้อนจากการรักษาหรือไม่ รักษาภาวะแทรกซ้อน ไม่เกิด ประเมินซ ้าและบันทึก Postoperative pain • Acute pain • Choices: - iv bolus/iv PCA/oral opioids - neuraxial opioids (spinal & epidural) - peripheral nerve blocks with LAs - NSAIDs and other medications • Effects of pain on systems CNS & Neuroendocrine 1. Secretes enkephalins, endorphins 2. Reflex escape response “Fight or Flight” - stimulated sympathetic nervous system - increased E and NE - inhibit peristalsis and secretion of digestive enzymes 3. Increasing CRH, ACTH, Cortisol from hypothalamus 4. Increasing glucagon and reduce insulin level CNS & Neuroendocrine 5. Increasing E & NE from adrenal medulla 6. Decreasing ADH = Na & water retention 7. Increasing renin & AT II secretion from adrenal gland 8. Increasing protein breakdown = reduce wound healing 9. Increasing IL-1 level = increase inflammatory effect Cardiovascular system Increasing sympathetic activity Hypertension increase myocardial Tachycardia O2 consumption Myocardial ischemia GI and Immune system • Depress immune system • Impaired GI function - delayed gastric emptying - reduce bowel motility, potential paralytic ileus - nausea & vomiting (also from CTZ) Respiratory system Limiting movement of thoracic & abdominal muscles Respiratory dysfunction Retained sputum and secretion (reluctant to cough) Reduction in vital capacity Hypoxia Cardiac complication, disorientation, confusion, and delayed wound healing KUB system Increasing CAs, aldosterone, ADH, cortisol, AT-II, and PGs (regulate urinary output, fluid & electrolyte balance, blood volume, and BP) Na & water retention Increase K+ excretion Fluid overload Increase cardiac workload Hypertension Musculoskeletal system Reflex muscle spasm, impaired muscle function Muscle fatigue Immobility Venous stasis Increase coagulability Increase risk of developing DVT Psychological & Cognitive function Acute stress-induced hormonal changes 1. Anxiety interrupt sleep pattern (insomnia) Depression interfere daily activity 2. Distressing cognitive impairment - disorientation - mental confusion - reduce ability to concentrate 3. Poorly-controlled acute pain --> chronic pain Neuropathic pain Definition • “Pain caused by a lesion or disease of the somato- sensory nervous system” • Clinical description (not a diagnosis) ; requires demonstrable lesion or disease that satisfies established neurological diagnostic criteria • Central and peripheral neuropathic pain Management • Pharmacotherapy • Physical and Psychotherapy • Interventions • Surgery • Lifestyle modifications • Alternatives • Neurostimulation (SCS) Pharmacotherapy • Gabapentin/Pregabalin (Neurontin®/Lyrica®) • Amitriptyline/Nortriptyline • Carbamazepine/Oxcarbazepine (Tegretol®/Trileptal®) • Duloxetine/Venlafaxine (Cymbalta®/Effexor®) • Tramadol (for acute exacerbation only) Cancer pain Medications • Opioids • Gabapentin and pregabalin • NSAIDs (for bone metastasis) • Antidepressants/antianxiety Nociceptive Neuropathic Cancer- Tumor- Visceral pain ยา pain cancer pain induced induced MBO* bone pain headache ดีมากสาหรับอาการ Opioids ดีมาก ปานกลาง ดีมาก ดี ปวดตลอดเวลา NSAIDs ดีมาก ไม่ดี ดีมาก ดี ไม่แนะนา Antidepressants น้อย ดีมาก ปานกลาง ไม่แนะนา ไม่แนะนา TCAsและSNRIs ดีสาหรับ visceral Gabapentinoids น้อย ดีมาก ดี ไม่แนะนา hyperalgesia ดีสาหรับ paroxysmal น้อย ยกเว้นใช้เป็นยา Carbamazepine ไม่ดี น้อย ไม่ดี sharp shooting pain กนั ชกั Bisphosphonates ไม่ดี ไม่ดี ดีเมื่อให้ระยะยาว ไม่ดี ไม่ดี ดีมากสาหรับ ดีสาหรับ liver capsule Corticosteroids ไม่แนะนา nerve/cord ปานกลาง ดีมาก distension compression Strong opioids • Morphine (Morphine, MST, Kapanol) • Meperidine (Pethidine) • Fentanyl (Fentanyl, Duragesic, Durogesic) • Methadone • Oxycodone Visceral Pain Visceral pain Clinical features : • Diffuse localization, deep, squeezing, crampy • Unreliable association with pathology • Referred sensation to cutaneous structures • Cutaneous or deep tissue hyperalgesia • Strong autonomic and emotional response may be evoked with minimal sensation Referred pain • Pain referred from a deep somatic or visceral structure to a distant region within the same segment • With/without hyperalgesia and hyperesthesia, deep tenderness, muscle spasm, and autonomic disturbances. • No changes in reflexes, no weakness or atrophy • Segments involved are identified (all somatic and visceral structures innervated are carefully examined for a pathologic process) • Ex: Shoulder pain in subphrenic abscess Visceral pain etiologies • Inflammation (acute and chronic), including inflammation caused by mechanical irritants (kidney stone) • Infection • Disruption of normal mechanical process (GI dysmotility) • Neoplasms (benign or malignant) • Alterations in nerves carrying sensations from the viscera • Ischemia Medications & Interventions • Opioid for cancer in origin • Antidepressants • Gabapentin/pregabalin • Sympathetic plexus block/neurolysis Musculoskeletal pain Pharmacotherapy . NSAIDs . Muscle relaxants Medications Oral medications - Acetaminophen (paracetamol) - NSAIDs - opioids = tramadol, codeine - tramadol + paracetamol (Ultracet®) - antidepressants/anticonvulsants IV medications - Opioids = morphine, pethidine, tramadol, fentanyl - NSAIDs = Parecoxib (Dynastat®), Ketorolac WHO step ladder modified by TASP Patient-controlled analgesia (PCA) Patient-controlled epidural analgesia (PCEA) 1. Improved pain control 2. Receive immediate delivery of pain med. 3. Patient control 4. Frequent but smaller dose, less side effects PCA variables • Bolus dose or PCA dose or demand dose (self-administered intermittently) • Lock out interval (time between dose) • Loading dose • Background infusion • Dose limit in 1 or 4 hour Using PCA - Patient education - Monitor O2 saturation (in high risk patient) 1. Pain scores at rest/movement 2. Side effects Sedation, N/V, pruritus, respiratory depression, urinary retention 3. Total amount of opioids delivered Neuraxial Opioids Spinal/epidural morphine - duration 18-24 hours/it depends - no sedatives or sleeping pills (except for order from anesthesiologist) - side effects : respiratory depression nausea and vomiting pruritus urinary retention Local anesthetic for epidural . 0.0625% - 0.15% Bupivacaine/Levobupivacaine . 1-2% Lidocaine with or without adrenaline Opioids • Morphine 1-5 mg bolus or epidural infusion at 0.005-0.02 mg/ml • Fentanyl 1-2 mcg/ml epidural infusion Peripheral nerve blocks - Local anesthetics only - Single shot or catheter - US-guided and/or peripheral nerve stimulator - 18-24 hours - Side effects : motor weakness catheter migration Acetaminophen Acetaminophen (paracetamol) • tablet 500 mg 1 tab oral prn/every 4-6 hrs • tablet 650 mg 1 tab oral prn/every 8 hrs • FDA Liver warning: Severe liver damage may occur if you take - more than 4,000 mg of acetaminophen in 24 hours - with other drugs containing acetaminophen - 3 or more alcoholic drinks everyday while using this product • FDA reminds health care professionals to stop dispensing prescription combination drug products with more than 325 mg of acetaminophen (4/28/2014) • Acetaminophen in both OTC and prescription products and the risk of attention deficit hyperactivity disorder (ADHD) in children born to women who took this medicine at any time during pregnancy. Liew Z, Ritz B, Rebordosa C, Lee PC, Olsen J. Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disorders. JAMA Pediatr 2014;168:313-20. NSAIDs Role of NSAIDs • Acute postoperative pain • Chronic musculoskeletal pain • Cancer-induced bone pain Evidence-based practice • Prevent and treat postoperative pain in ambulatory surgery • Decrease: opioid consumption early return of bowel function early recovery of physical activity increase patient satisfaction • No difference if given before or after surgery Maximum Drug mg Frequency dose/day Parecoxib (dynastat®) 40 IV q 12 h 80 Ketorolac 15, 30 IV q 8 h 90 Ibuprofen 200,400,600 q 4-6 h 2400 25,50 q 8 h Diclofenac 150 SR75,100 q 12-24 h Indomethacin 25 q 8-12 h 200 Naproxen 250 q 12 h 1000 Piroxicam 10,20 q 24 h 20 Meloxicam
Recommended publications
  • Current Awareness in Clinical Toxicology Editors: Damian Ballam Msc and Allister Vale MD

    Current Awareness in Clinical Toxicology Editors: Damian Ballam Msc and Allister Vale MD

    Current Awareness in Clinical Toxicology Editors: Damian Ballam MSc and Allister Vale MD April 2015 CONTENTS General Toxicology 9 Metals 44 Management 22 Pesticides 49 Drugs 23 Chemical Warfare 51 Chemical Incidents & 36 Plants 52 Pollution Chemicals 37 Animals 52 CURRENT AWARENESS PAPERS OF THE MONTH Acute toxicity profile of tolperisone in overdose: observational poison centre-based study Martos V, Hofer KE, Rauber-Lüthy C, Schenk-Jaeger KM, Kupferschmidt H, Ceschi A. Clin Toxicol 2015; online early: doi: 10.3109/15563650.2015.1022896: Introduction Tolperisone is a centrally acting muscle relaxant that acts by blocking voltage-gated sodium and calcium channels. There is a lack of information on the clinical features of tolperisone poisoning in the literature. The aim of this study was to investigate the demographics, circumstances and clinical features of acute overdoses with tolperisone. Methods An observational study of acute overdoses of tolperisone, either alone or in combination with one non-steroidal anti-inflammatory drug in a dose range not expected to cause central nervous system effects, in adults and children (< 16 years), reported to our poison centre between 1995 and 2013. Current Awareness in Clinical Toxicology is produced monthly for the American Academy of Clinical Toxicology by the Birmingham Unit of the UK National Poisons Information Service, with contributions from the Cardiff, Edinburgh, and Newcastle Units. The NPIS is commissioned by Public Health England Results 75 cases were included: 51 females (68%) and 24 males (32%); 45 adults (60%) and 30 children (40%). Six adults (13%) and 17 children (57%) remained asymptomatic, and mild symptoms were seen in 25 adults (56%) and 10 children (33%).
  • Symptomatic Pharmacotherapy in ALS: Data Analysis from a Platform-Based Medication Management Programme

    Symptomatic Pharmacotherapy in ALS: Data Analysis from a Platform-Based Medication Management Programme

    PostScript J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2020-322938 on 21 April 2020. Downloaded from LETTER during the observation. Riluzole was ALS were provided with a mean number the drug most commonly used (93% of 3.2 symptomatic drugs. However, of patients; n=2219). Symptomatic the number of drugs per patient varied Symptomatic pharmacotherapy drugs were assorted to pharmacological substantially (figure 1D). Furthermore, in ALS: data analysis from a domains and to the attainment of treat- we identified an increasing number of ment goals (figure 1B). An overview prescribed drugs per patient in correla- platform- based medication and ranking of symptomatic drugs are tion to advanced stages of King’s clinical management programme summarised in the online supplementary stages of ALS (figure 1C).4 file 2. Based on the number of patients who received the drug, the following top INTRODUCTION 10 symptomatic medicines were identi- DISCUSSION Although symptomatic medicines fied (in decreasing order): mirtazapine, The symptomatic medication was anal- constitute an important intervention ipratropium bromide, pirenzepine, ysed at specialised ALS centres in in amyotrophic lateral sclerosis (ALS), citalopram, lorazepam, baclofen, metam- Germany collaborating on multidisci- few systematic investigations into drug izole, quinine, fentanyl and tetrahydro- plinary managed care. Data assessment management have been reported so far.1 cannabinol:cannabidiol. Patients with was facilitated by the common use of Furthermore, symptomatic pharmaco- therapy is constantly evolving with an increasing number of drugs being used. Therefore, more detailed information on drug prescription must be obtained to monitor the current standards of care, identify potential shortcomings in drug management and elucidate progress in symptomatic pharmacotherapy.
  • Effects of Prophylactic Ketamine and Pethidine to Control Postanesthetic Shivering: a Comparative Study

    Effects of Prophylactic Ketamine and Pethidine to Control Postanesthetic Shivering: a Comparative Study

    Biomedical Research and Therapy, 5(12):2898-2903 Original Research Effects of prophylactic ketamine and pethidine to control postanesthetic shivering: A comparative study Masoum Khoshfetrat1, Ali Rosom Jalali2, Gholamreza Komeili3, Aliakbar Keykha4;∗ ABSTRACT Background: Shivering is an undesirable complication following general anesthesia and spinal anesthesia, whose early control can reduce postoperative metabolic and respiratory complications. Therefore, this study aims to compare the effects of prophylactic injection of ketamine and pethi- dine on postoperative shivering.Methods: This double-blind clinical trial was performed on 105 patients with short-term orthopedic and ENT surgery. The patients were randomly divided into three groups; 20 minutes before the end of the surgery, 0.4 mg/kg of pethidine was injected to the first group, 0.5 mg/kg of ketamine was injected to the second group, and normal saline was injected to the third group. After the surgery, the tympanic membrane temperature was measured at 0, 10, 20, and 30 minutes. The shivering was also measured by a four-point grading from zero (no shiv- ering) to four (severe shivering). Data were analyzed by one-way ANOVA, Kruskal Wallis, Chi-square 1Doctor of Medicine (MD), Fellow of and Pearson correlation. Results: The mean age of patients was 35.811.45 years in the ketamine Critical Care Medicine (FCCM), group, 34.811.64 years in the normal saline group, and 33.1110.5 years in the pethidine group. Department of Anesthesiology and The one-way ANOVA showed no significant difference in the mean age between the three groups Critical Care, Khatam-Al-Anbiya (P=0.645).
  • The In¯Uence of Medication on Erectile Function

    The In¯Uence of Medication on Erectile Function

    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
  • Clinical Manifestation of Juvenile and Pediatric HD Patients: a Retrospective Case Series

    Clinical Manifestation of Juvenile and Pediatric HD Patients: a Retrospective Case Series

    brain sciences Article Clinical Manifestation of Juvenile and Pediatric HD Patients: A Retrospective Case Series 1, , 2, 2 1 Jannis Achenbach * y, Charlotte Thiels y, Thomas Lücke and Carsten Saft 1 Department of Neurology, Huntington Centre North Rhine-Westphalia, St. Josef-Hospital Bochum, Ruhr-University Bochum, 44791 Bochum, Germany; [email protected] 2 Department of Neuropaediatrics and Social Paediatrics, University Children’s Hospital, Ruhr-University Bochum, 44791 Bochum, Germany; [email protected] (C.T.); [email protected] (T.L.) * Correspondence: [email protected] These two authors contribute to this paper equally. y Received: 30 April 2020; Accepted: 1 June 2020; Published: 3 June 2020 Abstract: Background: Studies on the clinical manifestation and course of disease in children suffering from Huntington’s disease (HD) are rare. Case reports of juvenile HD (onset 20 years) describe ≤ heterogeneous motoric and non-motoric symptoms, often accompanied with a delay in diagnosis. We aimed to describe this rare group of patients, especially with regard to socio-medical aspects and individual or common treatment strategies. In addition, we differentiated between juvenile and the recently defined pediatric HD population (onset < 18 years). Methods: Out of 2593 individual HD patients treated within the last 25 years in the Huntington Centre, North Rhine-Westphalia (NRW), 32 subjects were analyzed with an early onset younger than 21 years (1.23%, juvenile) and 18 of them younger than 18 years of age (0.69%, pediatric). Results: Beside a high degree of school problems, irritability or aggressive behavior (62.5% of pediatric and 31.2% of juvenile cases), serious problems concerning the social and family background were reported in 25% of the pediatric cohort.
  • Clinical Trial Protocol: 201

    Clinical Trial Protocol: 201

    Protocol: 201 Amendment 1 Neurana Pharmaceuticals, Inc. 02 May 2019 version 2.0 Confidential CLINICAL TRIAL PROTOCOL: 201 Title: Dose Ranging Study of Tolperisone in Acute Muscle Spasm of the Back, “STAR Study” Substance Tolperisone hydrochloride Identifier IND number 069169 Protocol Number 201 Sponsor Neurana Pharmaceuticals, Inc. 4370 La Jolla Village Drive, Suite 860 San Diego, CA 92122 Date of Protocol 02 MAY 2019 version Amendment # 2.0 1 Previous protocol 15Nov2018, version 1.0 (initial protocol) Sponsor Tom Wessel, M.D. Representative Chief Medical Officer Neurana Pharmaceuticals, Inc. Conduct: In accordance with the ethical principles that originate from the Declaration of Helsinki and that are consistent with International Council for Harmonisation Guidelines on Good Clinical Practice (ICH E6 GCP) and regulatory requirements as applicable Confidentiality Statement The present protocol is the sole property of Neurana Pharmaceuticals, Inc. and it may not in full or in part be passed on, reproduced, published or otherwise disclosed without the express permission of Neurana Pharmaceuticals, Inc. Page 1 of 60 Protocol: 201 Amendment 1 Neurana Pharmaceuticals, Inc. 02 May 2019 version 2.0 Confidential 1.2. Principal Investigator (PI) – Amendment 1 I have read and understand the contents of this clinical protocol 201, the STAR Study, and will adhere to the study requirements as presented, including all statements regarding confidentiality. In addition, I will conduct the study in accordance with current International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guideline for Good Clinical Practice and applicable regulatory requirements: PI SIGNATURE DATE (DD/MMM/YYYY) PRINTED NAME ____________________________________________ Page 3 of 60 Protocol: 201 Amendment 1 Neurana Pharmaceuticals, Inc.
  • Eperisone-Induced Anaphylaxis: Pharmacovigilance Data and Results of Allergy Testing

    Eperisone-Induced Anaphylaxis: Pharmacovigilance Data and Results of Allergy Testing

    Allergy Asthma Immunol Res. 2019 Jan;11(1):e18 https://doi.org/10.4168/aair.2019.11.e18 pISSN 2092-7355·eISSN 2092-7363 Original Article Eperisone-Induced Anaphylaxis: Pharmacovigilance Data and Results of Allergy Testing Kyung Hee Park,1,2 Sang Chul Lee,1,2 Ji Eun Yuk,2 Sung-Ryeol Kim,1,2 Jae-Hyun Lee,1,2 Jung-Won Park1,2* 1Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea 2Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea Received: Aug 6, 2018 ABSTRACT Revised: Sep 10, 2018 Accepted: Sep 22, 2018 Purpose: Eperisone is an oral muscle relaxant used in musculoskeletal disorders causing Correspondence to muscle spasm and pain. For more effective pain control, eperisone is usually prescribed Jung-Won Park, MD, PhD together with nonsteroidal anti-inflammatory drugs (NSAIDs). As such, eperisone may Division of Allergy and Immunology, have been overlooked as the cause of anaphylaxis compared with NSAIDs. This study aimed Department of Internal Medicine, Yonsei to analyze the adverse drug reaction (ADR) reported in Korea and suggest an appropriate University College of Medicine, 50-1 Yonsei-ro, diagnostic approach for eperisone-induced anaphylaxis. Seodaemun-gu, Seoul 03722, Korea. Tel: +82- 2-2228-1961; Fax: +82-2-393-6884; Methods: We reviewed eperisone-related pharmacovigilance data (Korea Institute of Drug E-mail: [email protected] Safety-Korea Adverse Event Reporting System [KIDS-KAERS]) reported in Korea from 2010 to 2015. ADRs with causal relationship were selected. Clinical manifestations, severity, Copyright © 2019 The Korean Academy of outcomes, and re-exposure information were analyzed.
  • Efficacy and Tolerability of Eperisone in Patients with Spastic Palsy: a Cross-Over, Placebo-Controlled Dose-Ranging Trial

    Efficacy and Tolerability of Eperisone in Patients with Spastic Palsy: a Cross-Over, Placebo-Controlled Dose-Ranging Trial

    European Review for Medical and Pharmacological Sciences 2009; 13: 365-370 Efficacy and tolerability of eperisone in patients with spastic palsy: a cross-over, placebo-controlled dose-ranging trial N. BRESOLINA, C. ZUCCAB, A. PECORIC AInstitute of Clinical Neurology, University of Milan, I.R.C.C.S. Ospedale Maggiore Policlinico, Milan (Italy) BNeurophysiopathology Unit, IRCCS “E. Medea”, Bosisio Parini (LC) (Italy) CMedical Department Eisai Srl, San Donato Milanese, Milano (Italy) Abstract. – Background and Objectives: Introduction Central muscle relaxants are a clinical option in patients with spastic palsy. Eperisone is a cen- tral muscle relaxant used in several conditions, Spastic palsy is a clinical condition character- but its therapeutic potential in spastic palsy ized by a velocity-dependent increase of muscle needs to be verified. This dose-ranging trial tone due to “parapyramidal” disturbance of the compares two doses of eperisone in patients inhibitory afferents to the second motor neuron1. with spastic palsy associated to cerebral or spinal diseases. This condition may represent a major impedi- Patients and Methods: In this randomized, ment to a full functional recovery and social re- placebo-controlled, double-blind, three-way habilitation in patients with lesions of the pyra- cross-over study, patients (18-75 years) with midal system, which could follow different dis- spastic palsy received eperisone 150 mg/day, eases, as stroke or multiple sclerosis. eperisone 300 mg/day, or placebo for 8 weeks. Central muscle relaxants, such as baclofen, ti- Treatment periods lasted for 14 days. Objective zanidine, diazepam and dantrolene, represent an clinical parameters (intensity of spasticity and physiological reflexes) and functional parame- interesting clinical option in patients with spastic ters (walking capability, capability to climb palsy, since they reduce spasticity and improve stairs, rigidity) were measured.
  • Spectrophotometric Method for Simultaneous

    Spectrophotometric Method for Simultaneous

    Hariyani Kaushik P et al. IRJP 2012, 3 (9) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 – 8407 Research Article SPECTROPHOTOMETRIC METHOD FOR SIMULTANEOUS ESTIMATION OF TOLPERISONE HYDROCHLORIDE AND DICLOFENAC SODIUM IN SYNTHETIC MIXTURE Patel Satish A, Hariyani Kaushik P* Department of Quality Assurance, Shree S. K. Patel College of Pharmaceutical Education & Research, Ganpat University, Ganpat Vidyanagar – 384012, Mehsana, Gujarat, India Article Received on: 19/07/12 Revised on: 22/08/12 Approved for publication: 04/09/12 *Email: [email protected] ABSTRACT The present manuscript describes simple, sensitive, rapid, accurate, precise and economical spectrophotometric method for the simultaneous determination of Diclofenac sodium and Tolperisone hydrochloride in bulk and synthetic mixture. The method is based on the simultaneous equations for analysis of both the drugs using methanol as solvent. Diclofenac sodium has absorbance maxima at 281 nm and Tolperisone hydrochloride has absorbance maxima at 255 nm in methanol. The linearity was obtained in the concentration range of 2-20 μg/ml and 2-20 μg/ml for Diclofenac sodium and Tolperisone hydrochloride, respectively. The concentrations of the drugs were determined by using simultaneous equations at both the wavelengths. The mean recovery was 100.6 ± 0.41 and 99.64 ± 0.50 for Diclofenac sodium and Tolperisone hydrochloride, respectively. The method was successfully applied to laboratory prepared synthetic mixture because no interference from the mixture excipients was found. The suitability of this method for the quantitative determination of Diclofenac sodium and Tolperisone hydrochloride was proved by validation. The proposed method was found to be simple and sensitive for the routine quality control application of Diclofenac sodium and Tolperisone hydrochloride in combination.
  • Pharmacogenetics of Ketamine Metabolism And

    Pharmacogenetics of Ketamine Metabolism And

    Pharmacogenetics of Ketamine Metabolism and Immunopharmacology of Ketamine Yibai Li B.HSc. (Hons) Discipline of Pharmacology, School of Medical Sciences, Faculty of Health Sciences, The University of Adelaide September 2014 A thesis submitted for the Degree of PhD (Medicine) Table of contents TABLE OF CONTENTS .............................................................................................. I LIST OF FIGURES ....................................................................................................IV LIST OF TABLES ......................................................................................................IV ABSTRACT ............................................................................................................... V DECLARATION .......................................................................................................VIII ACKNOWLEDGEMENTS ..........................................................................................IX ABBREVIATIONS .....................................................................................................XI CHAPTER 1. INTRODUCTION .................................................................................. 1 1.1 A historical overview of ketamine ........................................................................................ 1 1.2 Structure and Chemistry ....................................................................................................... 3 1.3 Classical analgesic mechanisms of ketamine ...................................................................
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL Et Al

    US 20140296.191A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL et al. (43) Pub. Date: Oct. 2, 2014 (54) COMPOSITIONS OF PHARMACEUTICAL (52) U.S. Cl. ACTIVES CONTAINING DETHYLENE CPC ............... A61K 47/10 (2013.01); A61 K9/0019 GLYCOL MONOETHYLETHER OR OTHER (2013.01); A61 K9/0048 (2013.01); A61 K ALKYL DERVATIVES 45/06 (2013.01) USPC ........... 514/167: 514/177; 514/178: 514/450; (71) Applicant: THEMIS MEDICARE LIMITED, 514/334: 514/226.5: 514/449; 514/338; Mumbai (IN) 514/256; 514/570; 514/179; 514/174: 514/533; (72) Inventors: Dinesh Shantilal PATEL, Mumbai (IN); 514/629; 514/619 Sachin Dinesh PATEL, Mumbai (IN); Shashikant Prabhudas KURANI, Mumbai (IN); Madhavlal Govindlal (57) ABSTRACT PATEL, Mumbai (IN) (73) Assignee: THEMIS MEDICARE LIMITED, The present invention relates to pharmaceutical compositions Mumbai (IN) of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl (21) Appl. No.: 14/242,973 ether or other alkyl derivatives thereofas a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene (22) Filed: Apr. 2, 2014 glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or as a solvent system in preparation of Such (30) Foreign Application Priority Data pharmaceutical compositions. The pharmaceutical composi Apr. 2, 2013 (IN) ......................... 1287/MUMA2013 tions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formu Publication Classification lations containing such pharmaceutical actives and are Suit able for use as injectables for intravenous and intramuscular (51) Int. Cl. administration, as well as for use as a preformed solution/ A647/ (2006.01) liquid for filling in and preparation of capsules, tablets, nasal A6 IK 45/06 (2006.01) sprays, gargles, dermal applications, gels, topicals, liquid oral A6 IK9/00 (2006.01) dosage forms and other dosage forms.
  • Topical Treatments of Skin Pain Associated with Hidradenitis Supprurativa

    Topical Treatments of Skin Pain Associated with Hidradenitis Supprurativa

    UC Davis Dermatology Online Journal Title Topical treatments of skin pain: a general review with a focus on hidradenitis suppurativa with topical agents Permalink https://escholarship.org/uc/item/4m57506k Journal Dermatology Online Journal, 20(7) Author Scheinfeld, Noah Publication Date 2014 DOI 10.5070/D3207023131 License https://creativecommons.org/licenses/by-nc-nd/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Volume 20 Number 7 July 2014 Review Topical treatments of skin pain: a general review with a focus on hidradenitis suppurativa with topical agents Noah Scheinfeld MD JD Dermatology Online Journal 20 (7): 3 Assistant Clinical Professor of Dermatology Weil Cornel Medical College Correspondence: Noah Scheinfeld 150 West 55th Street NYC NY 10019 (212) 991-6490 [email protected] Abstract Hidradenitis Supprurativa (HS) is a painful chronic follicular disease. Few papers have addressed pain control for this debilitating condition. Possible topical agents include tricyclic antidepressants, opioids, anticonvulsants, NSAIDs, NMDA receptor antagonists, local anesthetics and other agents. The first line agents for the topical treatment of the cutaneous pain of HS are diclonefac gel 1% and liposomal xylocaine 4% and 5% cream or 5% ointment. The chief advantage of topical xylocaine is that is quick acting i.e. immediate however with a limited duration of effect 1-2 hours. The use of topical ketamine, which blocks n- methyl-D-aspartate receptors in a non-competitive fashion, might be a useful tool for the treatment of HS pain. Topical doxepin, which available in a 5% commercially preparation (Zonalon®) , makes patients drowsy and is not useful for controlling the pain of HS .